Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12609000956202
Ethics application status
Approved
Date submitted
28/10/2009
Date registered
5/11/2009
Date last updated
2/09/2024
Date data sharing statement initially provided
2/09/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
Pharmacokinetics and Pharmacodynamics of Doxorubicin in Children, Adolescents and young adults with Newly Diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma A Multi-Institutional Cross-Discipline Non-Therapeutic Study
Scientific title
Pharmacokinetics and Pharmacodynamics of Doxorubicin in Children, Adolescents and young adults with Newly Diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma A Multi-Institutional Cross-Discipline Non-Therapeutic Study
Secondary ID [1] 1123 0
Australasian Sarcoma Study Group Number 3-10 AYA PK (ASSG 03-10 AYA PK)
Universal Trial Number (UTN)
Trial acronym
ASSG 03-10 AYAPK
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Osteosarcoma 252073 0
Ewing Family of Tumours 252126 0
Hodgkin Lymphoma 252127 0
Condition category
Condition code
Cancer 252278 252278 0 0
Children's - Leukaemia & Lymphoma
Cancer 252279 252279 0 0
Bone
Cancer 252280 252280 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental drug treatments are not part of this study. Patients will receive chemotherapy that is standard of care at their hospital. Blood samples for pharmacokinetics will be collected immediately prior to cycle 1 doxorubicin administration and at 0.5, 1, 3, & 6 hours after the end of the infusion, then at 24, 48 and 72 hours. Pharmacodynamics will be assessed using body composition assessments before patients commence chemotherapy. Body composition will be assessed by height and weight; bioelectric impedance analysis; X-ray of the wrist to estimate bone age and dual energy X-ray absorptiometry (DEXA) scan.
Intervention code [1] 241466 0
Other interventions
Comparator / control treatment
None
Control group
Uncontrolled

Outcomes
Primary outcome [1] 253148 0
To evaluate the effect of gender on the pharmacokinetics of doxorubicin in Adolescent and Young Adult with newly diagnosed Hodgkin lymphoma, osteosarcoma and Ewing family of tumours by comparing doxorubicin concentration-time curve area under the curve (AUC) against gender.
Timepoint [1] 253148 0
Cycle 1 of first infusion doxorubicin treatment
Secondary outcome [1] 262047 0
To evaluate the effect of gender and pubertal stage on the pharmacokinetics of doxorubicin in children and Adolescent and Young Adult (collectively) with newly diagnosed osteosarcoma and Ewing family of tumours by comparing doxorubicin concentration-time curve area under the curve (AUC) against gender.
Timepoint [1] 262047 0
Cycle 1 first infusion of doxorubicin treatment
Secondary outcome [2] 262048 0
To explore the relationship between doxorubicin pharmacokinetics and pharmacodynamics where pharmacodynamics is measured by worst toxicity grade and tumour response
Timepoint [2] 262048 0
Toxicity assessment at end of Cycle 1; response assessment at end of chemotherapy
Secondary outcome [3] 262049 0
To explore the relationship between toxicity and tumour response. Toxicity is measured using the Common Terminology Criteria for Adverse Events (CTCAE) version 3. Tumour response will be assessed using the hospital's standard response assessment measures, which depending on the disease may include post-resection tumour necrosis evaluation or radiological and nuclear imaging.
Timepoint [3] 262049 0
Toxicity assessment at end of Cycle 1; response assessment at end of chemotherapy

Eligibility
Key inclusion criteria
Newly diagnosed with osteosarcoma, Ewing family of tumours or Hodgkin lymphoma;
aged between 1 year and 40 years of age; planned treatment involves a standard doxorubicin-containing regimen; written informed consent from patient and/or patient’s parent or legal guardian
Minimum age
1 Years
Maximum age
40 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Impaired hepatic function such as known chronic liver disease, evidence of impaired synthetic function or transaminases raised >5 x normal; significant uncontrolled systemic illness as judged by investigator; females who are pregnant or breast feeding

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All patients diagnosed with Hodgkin lymphoma, osteosarcoma and Ewing family of tumours scheduled to receive chemotherapy including doxorubicin will be considered for the study
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
nonrandomised
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
not applicable
Phase
Not Applicable
Type of endpoint/s
Pharmacokinetics / pharmacodynamics
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/07/2010
Actual
5/09/2012
Date of last participant enrolment
Anticipated
Actual
9/04/2015
Date of last data collection
Anticipated
Actual
30/10/2016
Sample size
Target
110
Accrual to date
Final
79
Recruitment in Australia
Recruitment state(s)
NSW,VIC,QLD,WA
Recruitment postcode(s) [1] 2171 0
3000
Recruitment postcode(s) [2] 2172 0
3002
Recruitment outside Australia
Country [1] 26534 0
New Zealand
State/province [1] 26534 0
Auckland
Country [2] 26535 0
United Kingdom
State/province [2] 26535 0
London

Funding & Sponsors
Funding source category [1] 243938 0
Government body
Name [1] 243938 0
Victorian Cancer Agency
Country [1] 243938 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Australasian Sarcoma Study Group
Address
Peter MacCallum Cancer Centre
Research Division Level 2
St Andrews Place East Melbourne Vic 3002
Country
Australia
Secondary sponsor category [1] 251293 0
None
Name [1] 251293 0
Address [1] 251293 0
Country [1] 251293 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 244051 0
Peter MacCallum Cancer Centre
Ethics committee address [1] 244051 0
Ethics committee country [1] 244051 0
Australia
Date submitted for ethics approval [1] 244051 0
23/11/2009
Approval date [1] 244051 0
04/03/2010
Ethics approval number [1] 244051 0
09/73
Ethics committee name [2] 244052 0
Royal Childrens Hospital
Ethics committee address [2] 244052 0
Ethics committee country [2] 244052 0
Australia
Date submitted for ethics approval [2] 244052 0
23/11/2009
Approval date [2] 244052 0
23/08/2010
Ethics approval number [2] 244052 0
29135 A
Ethics committee name [3] 259257 0
Albury Wodonga Joint Hospitals Ethics Committee (Border Medical Oncology)
Ethics committee address [3] 259257 0
Ethics committee country [3] 259257 0
Australia
Date submitted for ethics approval [3] 259257 0
Approval date [3] 259257 0
17/02/2010
Ethics approval number [3] 259257 0
342/10/2
Ethics committee name [4] 259258 0
Royal Childrens Hospital Brisbane
Ethics committee address [4] 259258 0
Ethics committee country [4] 259258 0
Australia
Date submitted for ethics approval [4] 259258 0
Approval date [4] 259258 0
03/02/2010
Ethics approval number [4] 259258 0
HREC/10/QRCH/4
Ethics committee name [5] 259259 0
Childrens' Hospital Westmead (lead site NSW) and Sydney Children's Hospital (multi-site approval)
Ethics committee address [5] 259259 0
Ethics committee country [5] 259259 0
Australia
Date submitted for ethics approval [5] 259259 0
Approval date [5] 259259 0
25/01/2010
Ethics approval number [5] 259259 0
09/CHW/157 (Multicentre approval)

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 30429 0
Jayesh Desai
Address 30429 0
Peter MacCallum Cancer Centre
305 Grattan Street
Melbourne VIC 3000
Country 30429 0
Australia
Phone 30429 0
+61 3 85597902
Fax 30429 0
Email 30429 0
[email protected]
Contact person for public queries
Name 13676 0
Dr Sally Whyte
Address 13676 0
Peter MacCallum Cancer Centre
Research Division Level 2
St Andrews Place East Melbourne Victoria 3002
Country 13676 0
Australia
Phone 13676 0
+61 3 9656 3605
Fax 13676 0
+61 3 9656 5875
Email 13676 0
[email protected]
Contact person for scientific queries
Name 4604 0
Dr Sally Whyte
Address 4604 0
Peter MacCallum Cancer Centre Research Division Level 3 St Andrews Place East Melbourne Victoria 3002
Country 4604 0
Australia
Phone 4604 0
+61 3 9656 3605
Fax 4604 0
+61 3 9656 5875
Email 4604 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
De-identified IPD data collected throughout the study
When will data be available (start and end dates)?
Data available 3 months following publication, for an indefinite period
Available to whom?
Data are potentially available to:
• Researchers from not-for-profit organisations
• Commercial organisations
All data requests will be considered by the primary sponsor on a case by case basis. Requests must include a methodologically sound proposal. Specific conditions of use may apply and will be specified in a data sharing agreement (or similar) that the requester must agree to before access is granted.
Available for what types of analyses?
Any type of analysis. Assessed on a case-by-case basis.
How or where can data be obtained?
Access can be requested via the Health Data Australia catalogue (https://researchdata.edu.au/health/). Search for the ACTRN number in the catalogue to find datasets associated with this trial.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.